The briefing
Scientists at Kobe University developed off‑the‑shelf, mass‑producible immune cells that attacked solid human tumors engrafted in mice. The preclinical results point to a faster, more affordable path for cancer immunotherapy if confirmed in humans.
Original headline
Mass-producible immune cells fight solid human tumors in mice